Jubilant Life Sciences announces successful resolution to FDA warning letter for Montreal facility

Jubilant Life Sciences has received a communication from the US Food and Drug Administration (FDA), classifying its pharmaceutical manufacturing facility at Montreal, Canada as ‘Acceptable’. This resolves all issues raised by the FDA on the facility in February 2013 and subsequent communications.

The development follows completion of FDA’s review of the company’s responses post the February letter and the subsequent re-inspection conducted at Jubilant’s Montreal facility in September, 2013. This development successfully resolves the FDA issues at the Montreal facility.

EP News Bureau– Mumbai